UT Health San Antonio
Login

Suryavathi Viswanadhapalli, PhD

Assistant Professor

Currently seeking M.S. & Ph.D. students

Subspecialties: I developed the LIFR inhibitor EC359 for targeted therapy in ECa and specialize in therapy resistance, and drug development for women cancers.

Dr. Suryavathi Viswanadhapalli earned her Doctorate in Reproductive Toxicology from the University of Rajasthan, India, in 2007. Following this, she pursued a postdoctoral fellowship at the University of Virginia, where she focused on the genetic causes of infertility and endocrine disorders. She further expanded her expertise with a second postdoctoral fellowship at UT Health, specializing in hormonal carcinogenesis, therapy resistance, and drug development using endometrial, breast, and ovarian cancer models.

In 2018, Dr. Viswanadhapalli was appointed as a Research Instructor in the Department of Obstetrics and Gynecology at UT Health San Antonio. She now serves as an Assistant Professor, focusing her research on the development, characterization, and validation of new therapies for women's cancers. Her current research interests include developing small molecules targeting novel oncogenes, elucidating the mechanisms of action of new drugs, utilizing CRISPR/Cas9 screens, studying mechanisms of therapy resistance, and creating preclinical models of cancer progression, such as patient-derived explants (PDeX), organoids (PDO’s), and xenografts (PDX).